Physician profile
Paula Province Warren
NPI 1932336302
$114,302.01
in general payments reported to CMS, 2019-2025
64 companies · $62K in 2025
The $62K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,947 · 2020: $1,105 · 2021: $2,077 · 2022: $1,384 · 2023: $7,817 · 2024: $37K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $93K · Travel and Lodging: $8,859 · Food and Beverage: $4,186 · Consulting Fee: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $92,943.75 |
| Travel and Lodging | $8,858.65 |
| Food and Beverage | $4,186.00 |
| Consulting Fee | $1,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $56,866.98 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $49,981.56 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $564.80 | 2019-2025 | Ajovy |
| Amgen INC. | $382.79 | 2019-2022 | |
| Ucb, INC. | $381.05 | 2019-2024 | Briviact, Nayzilam |
| Acadia Pharmaceuticals INC | $366.81 | 2019-2022 | |
| Biogen, INC. | $341.12 | 2019-2022 | |
| Lundbeck LLC | $319.13 | 2019-2025 | Vyepti |
| Lilly USA, LLC | $314.42 | 2019-2025 | Emgality |
| Allergan, INC. | $311.12 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $268.18 | 2019-2023 | Ultomiris |
| Sunovion Pharmaceuticals INC. | $261.68 | 2019-2022 | |
| Genzyme Corporation | $222.59 | 2019-2021 | |
| Eisai INC. | $216.33 | 2020-2022 | |
| Novocure INC. | $181.22 | 2019-2025 | Optune Lua (Novottf-200t) |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.